High Court Refuses Ranbaxy's Lipitor Appeal

Law360, New York (April 2, 2007, 12:00 AM EDT) -- The U.S. Supreme Court refused Monday to intervene in Ranbaxy Laboratories Ltd.'s appeal of an appeals court ruling that upheld a Pfizer Inc. patent for the cholesterol-lowering drug Lipitor, the world’s best-selling drug.

“We are pleased to see that the Supreme Court has declined to intervene in the Appeals Court's decision supporting our very strong basic patent for Lipitor,” Pfizer said.

The development is the latest setback for India’s Ranbaxy in its costly—and, so far, largely unsuccessful—quest to have the patent for Lipitor invalidated in the...
To view the full article, register now.